Pharmacokinetics of Plasma Lamivudine (3TC), and Its Active Intracellular Anabolite 3TC-Triphosphate Over a 24 Hour Dosing Interval Following Administration of 3TC 300 mg and 150 mg Once Daily to HIV-Negative Healthy Volunteers.

Trial Profile

Pharmacokinetics of Plasma Lamivudine (3TC), and Its Active Intracellular Anabolite 3TC-Triphosphate Over a 24 Hour Dosing Interval Following Administration of 3TC 300 mg and 150 mg Once Daily to HIV-Negative Healthy Volunteers.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Dec 2011

At a glance

  • Drugs Lamivudine (Primary)
  • Indications Hepatitis B; HIV infections
  • Focus Pharmacokinetics
  • Acronyms ENCORE2
  • Most Recent Events

    • 20 Sep 2011 Primary endpoint 'Drug-concentration' has not been met.
    • 09 Feb 2011 Actual initiation date changed from 1 Sep 2009 to 1 Mar 2010 as reported by ClinicalTrials.gov.
    • 09 Feb 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top